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  INTRODUCTION 
 Non-steroidal anti-infl  ammatory drugs (NSAIDs) are widely used 
as analgesics (  1,2  ). Ibuprofen is the most commonly used non-
aspirin NSAID, with about one quarter of the US population aged 
17 years or older reporting ibuprofen intake in the past month 
( 2 ).  Th  e main factor that limits NSAID use is the deve  lopment 
of upper gastrointestinal (GI) adverse eff  ects including ulcers, 
complications such as bleeding, and dyspepsia. Strategies recom-
mended (  3  –  6  ) to decrease GI injury in NSAID users include 
co-therapy with misoprostol or proton-pump inhibitors and  /  or 
use of COX-2 selective inhibitors. 
 Histamine 2 -receptor antagonists (H2RAs) have not been recom-
mended for preventive therapy in NSAID users because, when 
given in standard doses, they signifi  cantly decrease duodenal but 
not gastric ulcers (  3,7  ). However, a Cochrane systematic review of 
placebo-controlled randomized trials   ≥  3  months  ( 7 )  identifi  ed 
one study showing a signifi  cant benefi  t of double-dose H2RAs 
in reducing both gastric ulcers (relative risk (RR)        =        0.42, 95  %   
confi   dence  interval,  0.18 – 0.97)  and  duodenal  ulcers  (RR    =    0.19, 
0.04 – 0.85)   (8)   .  Th  e RRs for proton-pump inhibitor vs. placebo 
co-therapy in the meta-analysis were 0.40 (0.32  –  0.51) for gastric 
ulcers and 0.19 (0.09  –  0.37) for duodenal ulcers (  7  ). 
                                                                         Double-Blind Randomized Trials of Single-Tablet 
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  on Behalf of the REDUCE-1 and -2 Study Investigators                         
    OBJECTIVES:       We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies 
to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efﬁ  cacy and Safety Studies)) 
to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen 
(HZT-501) signiﬁ  cantly reduces gastric and duodenal ulcers as compared with ibuprofen. 
    METHODS:       Patients (40  –  80 years) requiring daily non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) for   ≥   6 months 
with no prior ulcer complications, negative   H. pylori   stool test, and baseline endoscopy showing no 
ulcers and       <      5 erosions were randomly assigned in a 2:1 ratio to HZT-501 or identical-appearing 
ibuprofen 800    mg tablets thrice daily. Study endoscopies were done at 8, 16, and 24 weeks. After 
unblinding and initial analyses, 12 patients were found to be misclassiﬁ  ed as having gastric ulcers 
based on the adjudication of endoscopy reports, and analyses were re-run. 
    RESULTS:       In REDUCE-1, the primary end point analysis of gastric ulcers at 24 weeks with HZT-501 vs. 
ibuprofen was 12.7  %   vs. 22.9  %   (  P        =      0.0044) in the post-adjudication analysis. In REDUCE-2, the 
primary end point analysis of upper gastrointestinal (GI) ulcers was 13.0  %   vs. 20.5  %   (  P        =      0.0587) 
in the post-adjudication analysis. Prespeciﬁ  ed pooled analyses showed signiﬁ  cantly fewer gastric 
(12.5  %   vs. 20.7  %  ) and duodenal ulcers (1.1  %   vs. 5.1  %  ) with HZT-501 vs. ibuprofen. Proportional 
hazards analysis of multiple potential risk factors showed the risk ratio of upper GI ulcers with 
HZT-501 vs. ibuprofen was 0.46, 95  %   conﬁ  dence interval was 0.34  –  0.61. 
    CONCLUSIONS:       Combined results of the REDUCE studies indicate that double-dose famotidine plus ibuprofen, given 
as a combination tablet, decreases endoscopic upper GI ulcers as compared with ibuprofen alone.   
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 Although many national and international groups recommend 
protective therapy in NSAID users at increased risk of GI events 
(  3  –  6  ), most such patients are not prescribed protective therapy 
(  8,9  ). In addition, patients may not take their protective co-
therapy along with their NSAID, especially if they are not expe-
riencing any symptoms, and decreased adherence is associated 
with a signifi  cantly increased risk of developing upper GI ulcers 
or  bleeding  ( 10 – 13 ).  For  example,  van  Soest   et al.   ( 13 )  reported 
that the risk of an upper GI clinical event (bleeding, perforation, 
or symptomatic ulcer) in NSAID users at increased GI risk rose 
16  %   for every 10  %   decrease in the proportion of time a pro-
ton-pump inhibitor or H2RA was prescribed. Mechanisms that 
ensure adherence to protective therapy, such as the combination 
of an NSAID and a protective agent in one pill, theoretically 
should decrease the GI risk associated with the NSAID therapy. 
  We performed the REDUCE trials (Registration Endoscopic 
Studies to Determine Ulcer Formation of HZT-501 Compared 
with Ibuprofen: Effi   cacy and Safety Studies) to assess whether 
double-dose famotidine given in a single-tablet combination with 
ibuprofen (HZT-501 (ibuprofen 800   mg plus famotidine 26.6   mg); 
Horizon Pharma, Northbrook, IL) signifi  cantly reduces the pro-
portion of patients who develop gastric ulcers (REDUCE-1) 
or upper GI (gastric or duodenal) ulcers (REDUCE-2) during 
24 weeks of treatment as compared with ibuprofen in adult 
NSAID users.     
  METHODS   
  Patients 
  Male and female patients aged 40  –  80 years expected to require 
daily NSAID therapy for at least 6 months for pain and  /  or 
infl   ammatory conditions were eligible. Exclusion criteria 
included history of erosive esophagitis; history of GI complica-
tions (bleeding, perforated ulcer, gastric outlet obstruction due 
to an ulcer); history of NSAID-associated asthma exacerbations, 
acute renal failure, interstitial nephritis, or hepatitis; history of 
GI malignancy; history of myocardial infarction, unstable car-
diac arrhythmias, or stroke within 6 months of study entry; 
coronary artery bypass graft   surgery within 14 days of study 
entry; uncontrolled congestive heart failure or hypertension at 
entry; acid-suppressive therapy or misoprostol within 14 days 
before study entry or investigational drug or NSAIDs (includ-
ing aspirin         >        325      mg daily) within 30 days before study entry; 
ulcer or        >       5 erosions on screening upper GI tract endoscopy; or 
one of the following abnormalities on baseline laboratory test-
ing:  creatinine  clearance      <    45   ml / min;  aminotransferase      >    2.5 
times  upper  limit  of  normal;  fasting  blood  sugar      >    200   mg / dl; 
serum pregnancy test positive; serologic tests positive for human 
immunodefi  ciency virus, hepatitis B, or hepatitis C; or stool anti-
gen for   H. pylori   positive.   
  Study design 
  Patients were randomly assigned, using a computer-generated 
randomization schedule, from a central location utilizing an 
interactive voice response system with blinded medication kit 
number allocation in a 2:1 ratio to identical-appearing tablets of 
HZT-501  (800   mg  ibuprofen  and  26.6   mg  famotidine)  or  ibupro-
fen (800     mg) thrice daily for 24 weeks. Patients, care providers, 
and all study personnel were blinded to the treatment. Patients 
were stratifi   ed for two risk factors for ulcer development: 
concomitant use of low-dose aspirin (  ≤  325   mg  daily)  and / or  
anticoagulant medication and history of gastric or duodenal 
ulcer. In addition to the screening upper endoscopy at base-
line, patients had endoscopy at weeks 8, 16, and 24 (or earlier 
if premature study termination) of study therapy. Th  e  following 
medications were proscribed during the study: medications that 
may reduce ulcers (e.g., misoprostol, proton-pump inhibitors, 
and non-study H2RAs), non-study NSAIDs other than low-dose 
aspirin taken for cardiovascular prophylaxis. In addition, antac-
ids could not be taken for     >    3 days in any 2-week period; patients 
requiring further antacid therapy were to be discontinued from 
the trial. Th   e study medication was dispensed in an 8-week sup-
ply at 0, 8, and 16 weeks. Compliance was determined by pill 
count of returned bottles of study medication. Serum chemis-
tries, complete blood count, and prothrombin time were per-
formed at screening, week 8, week 16, and the fi  nal study visit 
(week 24 or earlier if early termination). Urinalysis was done at 
baseline and fi  nal visit.     
  End points and analysis 
 Th  e primary end point for REDUCE-1 was gastric ulcers iden-
tifi  ed at endoscopy during the 24-week study period, with three 
secondary end points: upper GI ulcers (gastric and duodenal), 
duodenal ulcers, and GI complications (bleeding, ulcer perfora-
tion, and gastric outlet obstruction due to ulcer). Th  e primary 
end point for REDUCE-2 was upper GI (gastric or duodenal) 
ulcers identifi  ed at endoscopy during the 24-week study period, 
with three secondary end points: gastric ulcers, duodenal ulcers, 
and GI complications. An endoscopic diagnosis of ulcer required 
unequivocal depth and diameter of   ≥  3   mm.  Th  e predefi  ned 
primary population for analysis included all patients who were 
randomized, received a dose of study medication, and had at least 
one study-mandated follow-up endoscopy. 
  A sample size for REDUCE-1 of 875 was calculated based on a 
90  %   power to detect a diff  erence of 6  %   vs. 14  %   in the incidence of 
gastric ulcers with a two-sided  α  of 0.05 and assuming a 15 %  drop-
out rate. A sample size for REDUCE-2 of 600 was calculated based 
on a 90  %   power to detect a diff  erence of 6  %   vs. 16  %   in the inci-
dence of upper GI ulcers with a two-sided   α   of 0.05 and assuming 
a 15  %   drop-out rate. Statistical comparisons were predefi  ned to be 
done with a fi  xed testing sequence (hierarchical) in the following 
order of primary followed by secondary end points: REDUCE-1: 
gastric ulcers, upper GI ulcers, duodenal ulcers, GI complications; 
REDUCE-2: upper GI ulcers, gastric ulcers, duodenal ulcers, GI 
complications. With this approach, the fi  rst null hypothesis that 
is accepted (i.e.,   P   ≥    0.05) will cause immediate acceptance of all 
subsequent null hypotheses in the sequence (subsequent compari-
sons will be considered not signifi  cantly diff  erent and no statistical 
comparison will be performed). Th  is approach also requires no 
  α   adjustment for multiple comparisons (  14  ). © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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 Th   e two diff  erent primary end points in the individual studies 
were chosen to address both the more clinically relevant end point 
of upper GI ulcers (gastric and  /  or duodenal) and the traditional 
US FDA (Food and Drug Administration) end point of gastric 
ulcers. In clinical practice, physicians and patients are concerned 
about preventing ulcers, whether they are gastric or duodenal, and 
many clinical trials use this primary end point. However, the FDA 
generally has approved antisecretory medications for prevention 
of gastric ulcers (e.g., lansoprazole and esomeprazole). Th  ese 
two trials were designed to be used for registration, and, in pre-
trial meetings, the FDA agreed to the use of the diff  erent end 
points in the two trials. 
  Comparison between treatment arms of the crude propor-
tions of patients with ulcers at 24 weeks with a Cochran  –  Man-
tel – Haenszel  test  stratifi  ed by the two randomization risk factor 
strata (use of low-dose aspirin and other anticoagulants, prior 
ulcer history) was specifi  ed as the primary statistical analysis at 
the time of sample size calculation and study initiation. Before 
study termination and unblinding, the primary analysis was 
changed to a comparison between treatment arms of the life table 
estimates of the proportion of patients with ulcers at 24 weeks 
employing a modifi  ed     χ    2   using the sum of squares from the 
life table in the error term, with the comparison of crude pro-
portions  using  the  Cochran – Mantel – Haenszel  test  maintained 
as a secondary analysis. Numbers-needed-to-treat (NNTs) 
and absolute risk reductions were calculated using crude 
proportions. 
  A pooled analysis of the patients in REDUCE-1 and -2 was 
prespecifi  ed, with the primary end point being upper GI ulcers, 
and the secondary end points being gastric ulcers and duodenal 
ulcers. Th   e proportion of patients developing ulcers was also pre-
specifi  ed to be assessed in the following subgroups: use of low-
dose aspirin and  /  or anticoagulants, prior ulcer history, age ( ≥  65 
vs.      <    65   years),  gender,  and  race.  In  addition,   post hoc   subgroup 
analysis included use of low-dose aspirin alone, and presence or 
absence of erosions at screening endoscopy. For comparison of 
Assessed for eligibility
(N=2,832)
REDUCE-1 (n=1,690); REDUCE-2 (n=1,142)  
Enrollment
Excluded (n=1,299)
REDUCE-1 (n=784); REDUCE-2 (n=515) 
▪ Prespecified criteria unmet (n=881)
▪ Declined to participate (n=322)
▪ Other reasons (n=96)
Randomized 2:1 HZT-501:Ibuprofen
(N=1,533)
REDUCE-1 (n=906); REDUCE-2 (n=627)
HZT-501 Ibuprofen
Allocated to HZT-501 intervention (n=1,022)
REDUCE-1 (n=607); REDUCE 2 (n=415) 
▪ Received allocated intervention (n=1,020)
REDUCE-1 (n=605); REDUCE-2 (n=415)
Allocated to ibuprofen intervention (n=513)
REDUCE-1 (n=301); REDUCE-2 (n=212)
▪Received allocated intervention (n=511)
REDUCE-1 (n=299); REDUCE-2 (n=212)
Allocation
Lost to follow-up (n=38)
Discontinued intervention (n=279)
▪ Death (n=0)
▪ Adverse event (n=62)
▪ Withdrew consent (n=91)
▪ Protocol violation (n=6)
Lost to follow-up (n=14)
Discontinued intervention (n=205)
▪ Death (n=1)
▪ Adverse event (n=38)
▪ Withdrew consent (n=52)
▪ Protocol violation (n=1)
Follow-up
▪ Discretion of investigator (n=25)
▪ Endoscopically diagnosed ulcer (n=84)
▪ Required excluded medication (n=2)
▪ Other (n=9)
▪ Discretion of investigator (n=17)
▪ Endoscopically diagnosed ulcer (n=85)
▪ Required excluded medication (n=4)
▪ Other (n=7)
Analysis
Had one or more post-screening 
endoscopy (n=951):
REDUCE-1 (n=561); REDUCE-2 (n=390)
▪ Excluded because no week 8 endoscopic 
examination within the allowed protocol visit 
window (n=21):
REDUCE-1 (n=11); REDUCE-2 (n=10)
Had one or more post-screening 
endoscopy (n=474): 
REDUCE-1 (n=276); REDUCE-2 (n=198)
▪ Excluded because no week 8 endoscopic 
examination within the allowed protocol visit 
window (n=22):
REDUCE-1 (n=14); REDUCE-2 (n=8)
Primary population analysis (n=930):
REDUCE-1 (n=550); REDUCE-2 (n=380)
Primary population analysis (n=452):
REDUCE-1 (n=262); REDUCE-2 (n=190)
    Figure 1  .                 Trial ﬂ  ow and patient disposition.   The American Journal of GASTROENTEROLOGY  VOLUME 107 | MARCH 2012   www.amjgastro.com
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    Table 1  .       Baseline characteristics of patients randomly assigned to HZT-501 or ibuprofen     
        Characteristic        Group   
            REDUCE-1 trial       REDUCE-2 trial       Pooled data   
       
    HZT-501 
(  N   =550)  
    Ibuprofen 
(  N   = 262)  
    HZT-501 
(  N   =380)  
    Ibuprofen 
(  N   =190)  
    HZT-501 
(  N   = 930)  
    Ibuprofen 
(  N   = 452)  
        Age (years)   
           Median   55.0   55.0   54.0   54.0   55.0   55.0 
           Range   40  –  80   40  –  78   39  –  79   40  –  78   39  –  80   40  –  78 
        Age class   %   (n)   
                 <      65 years    81.5  %   (448)    82.1  %   (215)    82.6  %   (314)    82.1  %   (156)    81.6  %   (762)    82.1  %   (371) 
             ≥   65 years   18.5  %   (102)    17.9  %   (47)    17.4  %   (66)    17.9  %   (34)    18.1  %   (168)    17.9  %   (81) 
        Gender   %   (n)   
           Male   32.0  %   (176)    31.3  %   (82)    34.2  %   (130)    28.4  %   (54)    32.9  %   (306)    30.1  %   (136) 
           Female   68.0  %   (374)    68.7  %   (180)    65.8  %   (250)    71.6  %   (136)    67.1  %   (624)    69.9  %   (316) 
        Race   %   (n)   
           White   77.1  %   (424)    77.5  %   (203)    81.6  %   (310)    84.7  %   (161)    78.9  %   (734)    80.5  %   (364) 
           Black   19.5  %   (107)    20.2  %   (53)    15.0  %   (57)    10.5  %   (20)    17.6  %   (164)    16.2  %   (73) 
           Other   3.5  %   (19)    2.3  %   (6)    3.4  %   (13)    4.7  %   (9)    3.4  %   (32)    3.3  %   (15) 
        Potential risk factors   %   (n)   
           Prior ulcer history    7.6  %   (42)    5.7  %   (15)    4.7  %   (18)    5.8  %   (11)    6.5  %   (60)    5.8  %   (26) 
             Use of low-dose aspirin 
and  /  or anticoagulants 
  17.1  %   (94)    13.4  %   (35)    15.5  %   (59)    13.2  %   (25)    16.5  %   (153)    13.3  %   (60) 
           Use of low-dose aspirin    16.7  %   (92)    12.6  %   (33)    15.0  %   (57)    13.2  %   (25)    16.0  %   (149)    12.8  %   (58) 
           Use of corticosteroids    0   0   0.3  %   (1)    0   0.11  %   (1)    0 
           Erosions at baseline    23.8  %   (131)    17.2  %   (45)    21.3  %   (81)    19.5  %   (37)    22.8  %   (212)    18.1  %   (82) 
          REDUCE, Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efﬁ  cacy and Safety Studies.         
  RESULTS 
 Th   e progress of the studies from enrollment through analysis is 
shown in the CONSORT diagrams in   Figure 1 .  Th  e  REDUCE-1 
trial took place from March 2007 through August 2008 at 68 cent-
ers in the United States and REDUCE-2 took place from March 
2007 through September 2008 at 68 centers in the United States. 
Th   e trials continued until their planned completion based on the 
prespecifi  ed sample sizes. Selected baseline characteristics of the 
primary population analyzed in the two study groups for each 
trial are shown in   Table 1  . Reason for NSAID use across both 
trials included pain (37.9  %  ), osteoarthritis (50.6  %  ), rheumatoid 
arthritis (3.5  %  ), and other (7.8  %  ). 
 Th   e initial results aft  er data lock and unblinding in REDUCE-1 
for the primary end point of proportion of patients with gastric 
ulcers at 24 weeks was 12.9  %   for HZT-501 and 25.3  %   for ibu-
profen (  P     =    0.0009;  NNT    =    11).  Th   e initial results for the primary 
end point in REDUCE-2 showed the proportions of patients with 
upper GI ulcers of 13.8  %   for HZT-501 and 22.6  %   for ibuprofen 
(  P     =    0.0304;  NNT    =    11). 
 Aft  er unblinding and performance of the statistical analyses, 
a review of endoscopy reports revealed that some patients with 
esophageal ulcers had been incorrectly assigned as having gastric 
subgroups  with      <    100  patients  across  the  combined  treatment 
arms, a Fisher  ’  s exact test was used. Th  e  independent  variables 
prior ulcer history, gender, age, low-dose aspirin use, baseline 
erosions, and therapy also were included in a proportional 
hazards model to determine the eff  ect on the dependent vari-
able of development of upper GI ulcer. Treatment-by-subgroup 
interaction was also assessed among these subgroups in the 
model. A   post hoc   fi xed eff  ect meta-analysis of the results of the 
two studies for end points of upper GI, gastric, and duo  denal 
ulcers was also performed (Review Manager 5.1, Cochrane 
Collaboration, Copenhagen, Denmark). 
 Statistical comparison between the study groups in the popula-
tion of all patients randomized was also prespecifi  ed for common 
adverse  events  (occurring  in      >    5 %   of  patients)  with  a  Cochran – 
Mantel  –  Haenszel test. In addition, we prespecifi  ed comparison 
of the proportion of patients who reported any symptom con-
sistent with dyspepsia (e.g., dyspepsia, upper abdominal pain 
or discomfort, epigastric pain or discomfort, stomach pain or 
discomfort; with and without nausea). 
  All study patients provided written informed consent and the 
study was approved by institutional review boards for all partici-
pating centers.       © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Results of the pooled analysis of the two studies are also shown 
in   Table 2  . When a fi  xed eff  ect meta-analysis of the two studies 
was performed, the diff   erences  and  95 %   confi  dence  intervals 
were identical to those shown in   Table 2   for the pooled analy-
ses of upper GI, gastric, and duodenal ulcers without evidence 
of heterogeneity (  I  2     =    0  for  upper  GI,  gastric,  and  duodenal  ulcer 
analyses). In addition, when the Cochran  –  Mantel  –  Haenszel 
analysis was re-run with study (REDUCE-1 or -2) included in 
the model, the   P   values for comparisons of all three end points 
remained      <    0.0001. 
 Th   e combined trial data of the primary population was used in 
a proportional hazards analysis to examine multiple risk factors in 
relation to development of upper GI ulcers. Treatment with HZT-
501 (vs. ibuprofen) was associated with a signifi  cantly lower risk 
ratio (RR) for upper GI ulcer formation in the initial (RR       =       0.44, 
0.33 – 0.58)  and  post-adjudication  analyses  (RR    =    0.46,  0.34 – 0.61). 
Patients   ≥   65 years had a signifi  cantly higher risk ratio of upper GI 
ulcer formation (initial: 1.47, 1.06  –  2.05; post-adjudication: 1.54, 
1.10  –  2.17) than those         <        65 years. RRs of upper GI ulcer forma-
tion for low-dose aspirin use were 1.40 (0.97  –  2.02) for initial and 
1.46 (1.004 – 2.11) for post-adjudication analyses and for prior ulcer 
history they were 1.55 (0.95  –  2.53) for initial and 1.65 (1.01  –  2.69) 
for post-adjudication analyses. Baseline erosions did not show a 
signifi  cant association with upper GI ulcer formation (initial: 1.20, 
0.86 – 1.67;  post-adjudication:  1.15,  0.82 – 1.62). 
 Th  e  eff  ect of treatment was also examined within subgroups for 
the combined studies. Th   e forest plot of these is shown in  Figure 3 . 
ulcers. An adjudication committee of two independent gastroenter-
ologists then reviewed all positive endoscopy reports to determine 
how many ulcers had been misclassifi  ed. In the primary population, 
fi  ve patients in REDUCE-1 (one HZT-501 (no ulcer), four ibuprofen 
(four esophageal ulcers)) and seven patients in REDUCE-2 (three 
HZT-501 (two no ulcer, one esophageal ulcer), four ibuprofen (one 
no ulcer, three esophageal ulcers)) had esophageal ulcers misclassi-
fi  ed as gastric ulcers or had no gastric ulcer present; duodenal ulcers 
were not aff  ected. Th   e results for the analyses were then re-run with 
these patients no longer listed as having gastric ulcers. Th  ese  post-
adjudication results are presented in   Table 2 .  In  REDUCE-1,  the 
primary end point of proportion of patients with gastric ulcers at 24 
weeks was 12.7 %  for HZT-501 and 22.9 %  for ibuprofen ( P     =    0.0044; 
NNT    =    12).  Th  e results for the primary end point in REDUCE-2 
showed the proportions of patients with upper GI ulcers of 13.0  %   
for HZT-501 and 20.5  %   for ibuprofen (  P     =    0.0587). 
  Assessment of the secondary ulcer end points in REDUCE-1 
revealed that signifi   cantly fewer patients receiving HZT-501 
developed upper GI ulcers in both the initial (NNT       =       9) and post-
adjudication  analysis  (NNT    =    10),  and  signifi  cantly fewer patients 
developed  duodenal  ulcers  (NNT    =    25).  Assessment  of  secondary 
end points in REDUCE-2 showed that the 6.7  %   reduction in life 
table estimate of gastric ulcers was not signifi  cant in the initial com-
parison ( P     =    0.0795) and the 5.3 %  reduction in the post-adjudication 
analysis was not formally tested based on the predefi  ned hierarchi-
cal testing sequence for the analysis. Th   e combined trial cumulative 
incidence for crude rate of ulcers by visit is shown in   Figure 2 . 
        Table 2  .       The proportions of patients (life table and crude rate) in the primary population developing an upper GI, gastric, or duodenal ulcer 
in the post-adjudication analysis (excluding esophageal or no ulcers previously labeled as gastric ulcers) over 24 weeks of treatment     
           REDUCE-1 trial       REDUCE-2 trial       Pooled results   
       
    HZT-501 
  N   =550   
    Ibuprofen 
  N   =262   
    HZT-501 
  N   =380   
    Ibuprofen 
  N   =190   
    HZT-501 
  N   =930   
    Ibuprofen 
  N   =452   
        Upper gastrointestinal (gastric or duodenal) ulcers   
           Life table   %     14.5  %  *   26.9  %     13.0  %     20.5  %     13.9  %  **   24.3  %   
           Crude rate   %   (  n  )   11.1  %   (61)***    21.8  %   (57)    9.7  %   (37)  *         17.9  %   (34)    10.5  %   (98)***    20.1  %   (91) 
             Absolute risk reduction 
(95  %   CI) 
  10.7  %       (5.0, 16.3  %  )       8.2  %   (1.9, 14.4  %  )       9.6  %   (5.4, 13.8  %  )     
        Gastric ulcers   
           Life table   %     12.7  %  *   22.9  %     12.2  %     17.5  %     12.5  %  **   20.7  %   
           Crude rate   %   (  n  )   9.8  %   (54)**    18.3  %   (48)    8.9  %   (34)  *     15.8  %   (30)    9.5  %   (88)***          17.3  %   (78) 
             Absolute risk reduction 
(95  %   CI) 
  8.5  %   (3.2, 13.8  %  )       6.8  %   (0.9, 12.8  %  )       7.8  %   (3.8, 11.8  %  )     
        Duodenal ulcers   
           Life table   %     2.1  %  *   7.1  %     0.9  %     6.6  %     1.6  %  *   6.9  %   
           Crude rate   %   (  n  )   1.3  %   (7)*    5.3  %   (14)    0.8  %   (3)*    4.7  %   (9)    1.1  %   (10)***    5.1  %   (23) 
             Absolute risk reduction 
(95  %   CI) 
  4.1 (1.2, 7.0  %  )       3.9  %   (0.8, 7.1  %  )       4.0  %   (1.9, 6.1  %  )     
          CI, conﬁ  dence interval; GI, gastrointestinal; REDUCE, Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efﬁ  cacy and 
Safety Studies.     
          *  P        <      0.05; **  P        <      0.001; ***  P        <      0.0001.     The American Journal of GASTROENTEROLOGY  VOLUME 107 | MARCH 2012   www.amjgastro.com
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No signifi  cant treatment-by-subgroup interactions were identifi  ed 
for the subgroups assessed (all   P   values      >    0.10). 
  Only two adverse event terms were reported in either study at a 
rate of   ≥  5 % :  dyspepsia  and  nausea.  Th   e rates for HZT-501 vs. ibu-
profen in the pooled results were 4.7  %   vs. 8.0  %   for dyspepsia and 
5.8  %   vs. 4.7  %   for nausea. However, the proportion of patients with 
one or more predefi  ned symptoms consistent with dyspepsia was 
not signifi  cantly diff  erent between HZT-501 and ibuprofen (12.3  %   
vs. 14.9  %  ). 
 GI complications were reported by investigators for three patients 
(0.6  %  ) given HZT-501 and zero given ibuprofen in REDUCE-1. 
Th  ese were GI bleeding episodes in which hemoglobin dropped 
1.6, 2.1, and 3.1     g  /  dl without clinical evidence of overt GI bleed-
ing, transfusions, or hospitalizations. Gastric erosions were noted 
at endoscopy in all three patients. No GI complications were 
reported in REDUCE-2. One death occurred in the two studies: a 
48-year-old female in the ibuprofen group died of cardiorespiratory 
arrest and multiorgan system failure attributed to acetaminophen 
toxicity.   
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    Figure 2  .                 The cumulative incidence (crude rate (  %  )) of ulcers at 8, 16, 
and 24 weeks in patients taking HZT-501 or ibuprofen (IBU) for the initial 
and post-adjudication analysis of the pooled data for the primary popula-
tion of REDUCE-1 and REDUCE-2 trials. GI, gastrointestinal; REDUCE, 
Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 
Compared with Ibuprofen: Efﬁ  cacy and Safety Studies.   
  DISCUSSION 
 Th   e goal of the REDUCE trials was to confi  rm the results of a sin-
gle smaller study by Taha  et al.   (  15  ), and demonstrate a signifi  cant 
decrease in NSAID-associated gastric and duodenal ulcers with 
double-dose famotidine, using a combination tablet of ibuprofen 
and famotidine. 
  Two studies of identical design were performed, as is gene  rally 
required when phase 3 trials are used to apply for regulatory 
approval. Th  e trials diff  ered only in their sample size and their 
primary vs. secondary end point (gastric ulcers followed by upper 
GI ulcers in REDUCE-1 and upper GI ulcers followed by gastric 
ulcers in REDUCE-2). Aft  er unblinding and initial analyses were 
performed, it was discovered on adjudication of endoscopy reports 
that 12 patients listed as having gastric ulcers actually had esopha-
geal ulcers or no ulcers. Th   erefore, analyses were re-run using the 
post-adjudication data, with these 12 patients no longer listed as 
having gastric ulcers. 
 Th   e larger REDUCE-1 trial demonstrated a signifi  cant decrease 
in the primary end point of gastric ulcers (  P     =    0.0044)  as  well  as 
in duodenal ulcers. Th   e smaller REDUCE-2 trial did not show a 
signifi  cant diff  erence in the post-adjudication primary analysis of 
life table estimates of upper GI ulcers, with a   P   value of 0.0587; the 
secondary statistical comparison of crude proportions of upper GI 
ulcers revealed a   P   value of 0.0070. Pooled analysis of the trials 
showed a signifi  cant decrease in upper GI ulcers with an NNT 
of 11, as well as signifi  cant decreases in both components, gastric 
ulcers and duodenal ulcers. 
  Multivariable analysis revealed a signifi  cant RR reduction in 
ulcers  of   ~ 55 %   with  HZT-501  aft  er adjustment for risk factors that 
may infl  uence the development of ulcers, such as age, ulcer history, 
aspirin use, and baseline erosions. Furthermore, the treatment 
0.25 0.5 1 2 4
Overall
Age < 65
Age ≥ 65
Prior ulcer
No prior ulcer
Low-dose aspirin
No low-dose aspirin
Male
Female
No baseline erosions
Baseline erosions
1,382
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442
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    Figure 3  .                 Forest plots of the relative risks (95  %   conﬁ  dence interval (CI)) 
for upper gastrointestinal ulcers for HZT-501 vs. ibuprofen (IBU) in sub-
group analyses of the pooled data for the primary population of REDUCE-1 
and REDUCE-2 trials. The sample sizes for each of the subgroups are 
shown at the right side. REDUCE, Registration Endoscopic Studies to 
Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efﬁ  cacy 
and Safety Studies.    © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Study Highlights  
    WHAT IS CURRENT KNOWLEDGE   
   3  Histamine  2  -receptor antagonists (H2RAs) are not generally 
recommen  ded to decrease gastrointestinal risk in 
non-steroidal anti-inﬂ  ammatory drug (NSAID) users. 
   3  H2RAs in standard doses do not signiﬁ  cantly decrease 
gastric ulcers in NSAID users. 
    WHAT IS NEW HERE   
   3  A single-tablet combination of double-dose famotidine 
plus ibuprofen reduced gastric and duodenal ulcers as 
compared with NSAIDs alone.                  
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 Ibuprofen was chosen as the NSAID studied because it is the most 
widely used non-aspirin NSAID in the United States ( 2 ). Although 
famotidine is generally given twice daily, ibuprofen at full doses for 
arthritis is typically given thrice daily. Th  e  double-dose  famotidine 
was therefore given as three daily doses of 26.6     mg in the combina-
tion tablet. A preliminary study suggested that 26.6     mg thrice daily 
produces gastric acid suppression similar to 40   mg twice daily aft  er 
1 day (  16  ). Also, oral administration of HZT-501 is bioequivalent 
to concurrent oral administration of equivalent separate doses of 
ibuprofen and famotidine (  17  ). 
 Previous trials have suggested that H2RAs may decrease upper GI 
symptoms in patients taking NSAIDs ( 18,19 ). We did not fi  nd a signi-
fi  cant decrease in the proportion of patients spontaneously report-
ing a composite of symptoms consistent with dyspepsia. Future 
studies should formally assess NSAID users with a patient-reported 
outcome instrument validated for NSAID-associated dyspepsia. 
  Upper GI complications such as bleeding are more important 
clinically than ulcers identifi  ed at a scheduled endoscopy, although 
results of endoscopic ulcer trials in NSAID users generally corre-
late with results in outcome trials assessing upper GI complications 
( 7,20 ). Nevertheless, our study was insuffi   cient in size and duration 
to reasonably assess complications, and the results do not demon-
strate a benefi  t in complications. No patients had overt bleeding, 
obstruction, or perforation. Two patients in the HZT-501 arms 
(and none in the ibuprofen arms) had asymptomatic hemoglobin 
decreases      >    2.0   g / dl,  the  level  typically  used  in  outcome  trials  as 
a clinically relevant hemoglobin drop (  21,22  ), and a third had a 
1.6   g / dl decrease. Chan  et al.  ( 22 ) recently showed that such hemo-
globin drops are much more common than overt complications 
in patients taking an NSAID plus antisecretory therapy, and that a 
majority are probably of small intestinal origin. Our patients with 
hemoglobin drops had gastric erosions noted, although no exami-
nation was performed to assess potential small intestinal injury. 
 Very few patients were on antiplatelet agents other than low-dose 
aspirin so our study is unable to assess any potential interactions 
of famotidine with clopidogrel. Famotidine, like ranitidine and 
unlike cimetidine, shows little or no interaction with the hepatic 
cytochrome P450 system (  23  ). 
  In summary, the combined results of two studies indicate that 
double-dose famotidine plus ibuprofen, given as a combination 
tablet, decreases endoscopic upper GI ulcers as compared with 
ibuprofen alone. Use of a combination tablet theoretically should 
improve adherence to antisecretory therapy as compared with use 
of separate individual NSAID and antisecretory agents, but future 
studies will be necessary to prospectively study adherence and the 
eff  ect on endoscopic or clinical outcomes.           
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